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Summary
 
Classical antigen presentation by major histocompatibility complex class I molecules involves
cytosolic processing of endogenously synthesized antigens by proteasomes and translocation of
processed peptides into the endoplasmic reticulum (ER) by transporters associated with antigen
presentation (TAP). Alternative pathways for processing of endogenous antigens, generally in-
volving the ER, have been suggested but not fully proved. We analyzed the potential for class
I presentation of proteolytic maturation of secretory antigens in the exocytic pathway. We
found that hepatitis B (HB) virus secretory core protein HBe can efficiently deliver COOH-
terminally located antigenic peptides for endogenous class I loading in the absence of TAP. An-
tigen presentation to specific cytotoxic T lymphocytes correlates with protein maturation at the
COOH terminus, since modification of maturation and transport of HBe through the secretory
pathway alters antigen presentation. Both maturation and a necessary processing step occur in
the Golgi or post-Golgi compartment. Antigen presentation is independent of proteasome ac-
tivity, but inhibitors of the 
 
trans
 
-Golgi network resident protease furin inhibit both HBe matu-
ration and antigen presentation. These results define a new antigen processing pathway located
in the secretory route, with a central role for proteolytic maturation mediated by the subtilisin
protease family member furin as an efficient source for antigen presentation.
Key words: antigen processing • major histocompatibility complex class I • secretory pathway • 
furin • virus
 
M
 
ajor histocompatibility complex (MHC) class I mol-
ecules display a repertoire of endogenously processed
peptides to CD8
 
1
 
 T lymphocytes. These perform an im-
munological surveillance in search of possible antigenic
peptides to destroy those presenting cells synthesizing for-
eign or abnormal proteins. Peptides bound by class I mole-
cules have a typical size of 8–10 amino acids because their
NH
 
2
 
 and COOH termini are anchored in pockets that es-
tablish an extensive network of hydrogen bonds and con-
tribute significantly to the overall affinity and thermal sta-
bility of the complex (1, 2). The majority of peptides are
generated during degradation of proteins in the cytosol and
are transported into the endoplasmic reticulum (ER)
 
1
 
 by
the MHC-encoded peptide transporter associated with an-
tigen processing (TAP), where they bind nascent class I
molecules (3, 4). The quality control machinery of the ER
determines that only those complexes with the proper con-
formation and thermal stability travel through the exocytic
route to the cell membrane.
It is currently agreed that cytosolic proteasomal degrada-
tion is the major source of peptides for class I binding and
presentation to CTLs. The proteasome is a large 26S com-
plex that degrades ubiquitinated proteins and contains the
20S proteolytic core, a large multicatalytic complex of 700
kD composed of 14 different subunits (5). In vitro experi-
ments show that proteolytic digestion of full-length pro-
teins or synthetic peptide precursors by the proteasome
can, in some cases, generate the same antigenic peptides
presented in vivo, in conjunction with many other prod-
ucts (6, 7). The differential efficacy of in vivo processing of
related substrates can be mimicked in vitro with purified
proteasomes (8). Natural modulators or synthetic inhibitors
of proteasomes enhance or prevent in vivo antigen presen-
tation, respectively, by MHC class I molecules (9–11). Lac-
tacystin, a yeast metabolite that specifically inhibits protea-
some by covalent binding to the conserved NH
 
2
 
-terminal
threonine of 
 
b
 
 catalytic subunits without inhibiting other
proteases (12), inhibits antigen presentation to CTLs, al-
though it does not fully prevent stable MHC class I mole-
 
1
 
Abbreviations used in this paper:
 
 BFA, brefeldin A; ER, endoplasmic reticu-
lum; HBV, hepatitis B virus; rVV, recombinant vaccinia virus; TAP,
transporter associated with antigen processing; TGN, 
 
trans
 
-Golgi net-
work.
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cule assembly. In addition, the majority of antigenic pep-
tides are generated in the cytosol, since cell mutants lacking
TAP transporters for peptide translocation into the ER
have severely reduced levels of class I molecules at the cell
surface (13). Thus, generation of most antigenic peptides
appears to require cleavage by proteasomes in the cytosol.
What remains to be demonstrated is the implication of
other cytosolic degradative pathways in antigen generation,
and whether proteasomes generate the final antigenic pep-
tides or intermediate precursors that must be trimmed to
the optimal length. The latter may well be the case, as TAP
efficiently translocates 9–13 amino acid–long peptides, al-
though efficacy rapidly decreases for longer peptides (14).
Recent studies with minigenes encoding epitope-contain-
ing oligopeptides show that trimming to actual epitope size
may occur without the involvement of proteasomes (15–
17).
 
 
 
Trimming may take place in the cytosol or inside the
ER (18), or along the secretory pathway (19).
Cytosolic peptides do not constitute the only source of
peptides for class I binding as seen in the TAP
 
2
 
 mutants.
Bound peptides in these cells derive from signal sequences
that have direct access to the ER, where they are liberated
by signal peptidase without involvement of proteasomes
(20). In addition, ER-targeted polypeptide constructs con-
taining natural epitopes can be trimmed effectively, proba-
bly by action of aminopeptidases, to generate the appropri-
ate peptide for class I loading (21, 22), but full-length
proteins could not be processed. Additional evidence for
alternative processing is given by presentation in TAP
 
2
 
mutant cells of epitopes corresponding to transmembrane
regions of multiple membrane-spanning proteins (23), but
it is unknown if these peptides are generated in the ER or
in the cytosol, having access to the reticulum by a TAP-
independent mechanism. In one case, an ER resident protein
inserted in the membrane through an unknown mecha-
nism independent of the translocon is able to provide anti-
genic peptides in a TAP-independent way, generated ei-
ther in the ER, probably by action of signal peptidases, or,
in some special constructs, by an unknown mechanism in
the cytosol (24). The only additional full-length protein
that appears to be processed in the ER-secretory pathway
for antigen presentation is the HIV-1 env protein, although
the proteases involved are unknown and therefore formal
proof for processing in this pathway is lacking (25).
In this study, we have analyzed antigen processing of a
protein known to mature in the secretory pathway in a
process that involves proteolytic release of its COOH-ter-
minal region. Endoproteolytic cleavage of proproteins is a
common posttranslational modification of many peptide
hormones, neuropeptides, growth factors, viral glycopro-
teins, etc., in the exocytic transport route, involving in
most cases proteases with specificity for dibasic residues
(26). We examined if this processing could be a source for
generation of peptides appropriate for class I loading and
antigen presentation. The natural occurrence of the hepati-
tis B virus (HBV) core protein both in the exocytic path-
way and in the cytosol due to alternative usage of a precore
signal sequence allowed us to compare processing in the
secretory compartment with the classical pathway for class I
presentation. In this way, we minimized artificial mistargeting
of proteins to a different compartment, which may result in
rapid degradation of the mislocated protein, and we thus pro-
vide a good control for studying antigen processing under
normal conditions (27, 28). We used recombinant vaccinia
viruses (rVV) encoding chimeric proteins that contain a mu-
rine CMV epitope at two different positions within the pro-
tein, both in the cytosolic and ER-targeted forms, to demon-
strate efficient antigen processing in the secretory pathway,
and for the first time identify proteases of the exocytic route
involved in this new pathway of class I presentation.
 
Materials and Methods
 
Materials.
 
Tunicamycin, brefeldin A (BFA), and cycloheximide
were purchased from Sigma Chemical Co. (St. Louis, MO). Pepsta-
tin was purchased from Boehringer Mannheim Corp. (Indianapolis,
IN). Lactacystin was either a gift from Dr. S. Omura (Kitasato Insti-
tute, Tokyo, Japan) or purchased from E.J. Corey (Harvard Univer-
sity, Cambridge, MA). The decanoyl-peptidyl-chloromethylketone
decRVKR-CMK was a gift from Dr. W. Garten (Marburg Univer-
sity, Germany [29]). 9pp89 peptide was synthesized in a peptide
synthesizer (model 431A; Applied Biosystems, Inc., Foster City,
CA), purified, and analyzed by reversed-phase HPLC.
 
Cell Lines.
 
The P13.1 cell line, a derivative from P815 mas-
tocytoma cells (H-2
 
d
 
) by transfection with the lacZ gene encod-
ing 
 
b
 
-galactosidase, was provided by Dr. H.G. Rammensee
(Tübingen University, Germany [30]). The TAP-deficient hu-
man lymphoblastoid cell line T2 was provided by Dr. G. Häm-
merling (German Cancer Research Center, Heidelberg, Ger-
many). Murine Ltk
 
2
 
 fibroblasts (H-2
 
k
 
) were obtained from Dr.
U.H. Koszinowski (Munich University, Germany). L
 
d
 
 gene
transfectants T2/L
 
d
 
 and L/L
 
d
 
 were provided by Dr. P. Cresswell
(Yale University, New Haven, CT [31]) and Dr. U.H. Koszi-
nowski (32), respectively. All cell lines were maintained in
IMDM supplemented with 10% FCS and 1% 2-ME, and incu-
bated at 37
 
8
 
C under 5% CO
 
2
 
.
 
rVV and Viral Infections.
 
The rVV cC-A9A and sC-A9A en-
code chimeric proteins containing the murine CMV antigenic
nonamer 9pp89 (YPHFMPTNL) flanked by penta-alanine and
inserted at position 179 at the COOH terminus of the HBV pre-
core protein. The chimeric protein cC-A9A (named HBc/C/
A
 
5
 
9A
 
5
 
 in reference 33) is expressed in the cytosol, as it lacks an
NH
 
2
 
-terminal signal sequence. The wild-type signal sequence of
the HBV precore protein was replaced with the one from influ-
enza virus hemagglutinin (denoted s) in rVV sC-A9A, sN-9, and
sN-9S. The rVV sN-9 and sN-9S express chimeric proteins con-
taining 9pp89 at position 3 at the carrier protein NH
 
2
 
 terminus.
The rVV sN-9S differs from sN-9 by an exchange of a Gly resi-
due next to the pp89 epitope for Ser that generates a glycosyla-
tion site, YPHFMPTNLS. The rVV eN-A9A (named HBe/N/
A
 
5
 
9A
 
5
 
 in reference 33) encodes a chimeric protein containing
9pp89 flanked by penta-alanine and inserted at position 3 of the
carrier protein with the wild-type signal sequence (denoted e).
All rVV were generated according to Del Val et al. (33). The
generation of rVV that encode the hemagglutinin signal sequence
has been described (34).
T2/L
 
d
 
 cells were infected as described (19) for 1 h with rVV at
40 PFU/cell at a concentration of 10
 
7
 
 cells/ml in PBS with 0.2%
BSA. After adsorption, cells were washed three times to eliminate
virus inoculum and then were diluted tenfold in IMDM plus 
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7.5% FCS. This was followed by an additional 12-h incubation
for CTL assays or a 15-h incubation for Western blot analysis. For
CTL assays, P13.1 cells were infected for 3 h as described (19).
For Western blot analysis, infected P13.1 cells were incubated for
5 h. To study chimeric protein glycosylation, tunicamycin was
added to cells at a final concentration of 5 
 
m
 
g/ml after viral ad-
sorption. To study the effect of BFA, infected cells were incu-
bated with BFA after adsorption, at a concentration of 1 
 
m
 
g/ml
for cytolysis or 0.5 
 
m
 
g/ml for Western blot analysis. To study the
effect of lactacystin, P13.1 cells were treated with 30 or 100 
 
m
 
M
lactacystin after viral adsorption. Because T2/L
 
d
 
 cells showed
toxic effects at higher lactacystin concentrations and longer infec-
tion times, they were pretreated for 30 min and infected for 1 h
in the presence of 5 
 
m
 
M lactacystin and then incubated with 10
 
m
 
M lactacystin during 4 h infection (24). To analyze protein mat-
uration, cells were incubated with pepstatin or decRVKR-CMK
after viral adsorption.
 
Cytolytic Assays.
 
Polyclonal 9pp89-specific CTLs were gen-
erated from mice immunized with murine CMV as described
previously (16). Recombinant human IL-2, used for the long-
term propagation of 9pp89-specific CTL lines, was provided by
Hoffmann-La Roche (Basel, Switzerland). Infected cells were la-
beled for 1 h with Na
 
51
 
CrO
 
4
 
, washed, and incubated with CTLs
at known E/T ratios in a standard 3–5 h chromium release assay
(32). For controls with synthetic 9pp89, peptide was incubated
with target cells during 
 
51
 
Cr labeling. When cells had been treated
with BFA during infection, the CTL assay was performed in the
presence of BFA 0.5 
 
m
 
g/ml. All other CTL assays were performed
in the absence of inhibitors. Coculture experiments were per-
formed as described previously with minor modifications (22). In
brief, cold T2/L
 
d
 
 cells infected with the testing rVV were mixed
for 2 h with equal amounts of 
 
51
 
Cr-labeled T2/L
 
d
 
 cells infected
with control rVV, and CTLs were then added. Cycloheximide at
a final concentration of 10
 
2
 
4
 
 M was included during the coculture
and CTL assay to prevent coinfection with the coculturing virus.
 
Western Blot.
 
Chimeric proteins in the infected cells and se-
creted to the medium were analyzed by Western blot. Cell pellets
or supernatant medium concentrated by Centricon 30 (Amicon
Inc., Beverly, MA) corresponding to 10
 
6
 
 cells were loaded onto
polyacrylamide gels. After SDS-PAGE separation, proteins were
electrotransferred to Immobilon-P membranes (Millipore Corp.,
Bedford, MA) and developed with a rabbit polyclonal anti-HBe
serum by standard ECL procedures according to the manu-
facturer’s protocol (Amersham Pharmacia Biotech, Inc., Piscat-
away, NJ). The antiserum was produced by repeated injection in
Freund’s adjuvant of purified HBV core particles (a gift of Dr.
H.-J. Schlicht, Ulm University, Germany), and recognized both
HBe and HBc.
 
Isolation and Quantitation of Naturally Processed Peptides.
 
T2/
L
 
d
 
 and T2 cells (2 
 
3
 
 10
 
8
 
) were infected with rVV at a multiplicity
of infection of 40 PFU/cell for 1 h. For L/L
 
d
 
 and Ltk
 
2
 
 cells (2 
 
3
 
10
 
8
 
), a multiplicity of infection of 10 was used. Cells were then
incubated overnight in IMDM plus 7.5% FCS. Naturally pro-
cessed peptides were extracted from whole cells with TFA and
purified essentially as described previously (33). Macrosep 10K
(Filtron Technology Corp., Northborough, MA) centrifugal
concentrators were used for the isolation of low molecular weight
peptides. Reverse-phase HPLC was performed using a Smart sys-
tem (Amersham Pharmacia Biotech, Inc.) equipped with a C18
column, and peptides were eluted with a 20–37% CH
 
3
 
CN gradi-
ent in 0.1% TFA. As internal standards in all HPLC runs, two
pp89-unrelated peptides were included. Fractions of HPLC runs
were tested in triplicate with pp89-specific CTLs by incubating
with P13.1 target cells that had been cultured overnight at 26
 
8
 
C
to maximize binding of exogenous peptide. Serial dilutions of
positive fractions of HPLC runs were further tested.
 
Results
 
TAP-independent Presentation of an HBe-inserted Epitope.
 
The C gene of human HBV codifies for a core protein that
is naturally found in two forms: a secretory HBe form and a
cytosolic HBc form (see scheme in Fig. 3 
 
A
 
). Alternate ini-
tiation codon usage adds a 29 amino acid–long pre-C signal
to the HBc p21c protein that targets it to the ER (p25
form), where removal of its 19 amino acid–long signal pep-
tide generates the immature HBe (p22) protein with an ex-
tended 10 amino acid–long NH
 
2
 
 terminus compared with
HBc. HBe is processed in the secretory pathway by an un-
known mechanism involving removal of 34 residues of its
COOH-terminal region, generating a secretory p17e form
that is secreted to the external medium (35). This secretion
is specific and occurs concomitantly with biosynthesis.
Other forms are also found in the external medium after
long periods of culture or high levels of protein expression
(36). Under some experimental conditions, translocation to
the ER is not complete and some HBe protein can be found
in the cytosol (37). Substitution of the pre-C signal sequence
by the influenza virus hemagglutinin signal sequence, gener-
ating a final product after signal peptidase cleavage of the same
length as HBe but differing at the 10 NH
 
2
 
-terminal amino
acids (hereafter sHBe), results in the complete translocation of
HBe to the ER, where the same processing machinery gen-
erates the homologous p17 secretory protein (34).
The existence of these two natural forms of a protein
that differ in their intracellular location and maturation
provided the opportunity to analyze the influence in anti-
gen presentation by MHC class I molecules of processing
in the secretory pathway. We were interested in studying if
proteolytic maturation of a protein in the exocytic pathway
could be a mechanism of antigen processing for class I pre-
sentation. For that purpose, we used a set of rVV that cod-
ify for HBe-related chimeric proteins consisting of either
the cytosolic or the secretory proteins with the immu-
nodominant 9-mer epitope of the murine CMV pp89 pro-
tein (YPHFMPTNL, or 9pp89; references 3, 32, and 33)
flanked on both sides by five alanine residues (denoted
A9A) and located at position 179 close to the COOH ter-
minus (named C-A9A). Polyclonal CTLs specific for the
9pp89 epitope presented by L
 
d
 
 were used to analyze anti-
gen processing and presentation by P13.1 target cells in-
fected with the different rVV. As seen in Fig. 1, both cyto-
solic and secretory forms of the chimeric proteins were
properly processed to the antigenic form of the 9pp89
epitope, since they were recognized by the L
 
d
 
-restricted
CTLs. On the contrary, on TAP
 
2
 
 T2/L
 
d
 
 cells, both pro-
teins showed a different capacity to provide 9pp89 peptide
to L
 
d
 
 (Fig. 1). As expected, 9pp89 in the cytosolic cC-A9A
protein was not presented, as it cannot be transported to
the ER. Surprisingly, cells infected with the secretory rVV
construct sC-A9A were recognized and lysed by CTLs. 
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When we used rVV codifying for either secretory or cyto-
solic proteins with 9pp89 located at the NH
 
2
 
 terminus, a
region not affected by proteolytic maturation, TAP
 
2
 
infected cells were not recognized. Both types of chimeric
proteins were properly processed in TAP
 
1
 
 P13.1 cells in-
dependently of their intracellular targeting (Fig. 1, and data
not shown). Thus, 9pp89 in the ER-targeted sC-A9A pro-
tein is correctly processed and gains access to the secretory
pathway for L
 
d
 
 binding and presentation without the need
for peptide transporters, suggesting that antigen processing
occurs in the secretory pathway.
 
Endogenous Processing of the TAP-independent Epitope.
 
A po-
tential alternative explanation to the generation of antigenic
peptide in the exocytic pathway is that some sC-A9A mol-
ecules are processed in the cytosol or in other cellular com-
partments to a form that secretes 9pp89 or precursor anti-
genic peptides to the external medium that subsequently
may bind to L
 
d
 
 at the cell surface. To exclude this possibil-
ity, we first checked that antigenic peptide was absent in
the rVV inoculum. rVV–sC-A9A inoculum was adsorbed
to T2/L
 
d
 
 cells for 1 h just before 
 
51
 
Cr labeling for the T cell
assay. T2/L
 
d
 
 cells treated in this way were not sensitized
(Fig. 2 
 
A
 
, 
 
top bar
 
), whereas cells incubated with synthetic
9pp89 peptide were readily lysed (
 
second bar
 
). Second, we
incubated uninfected labeled target cells with the superna-
tant from cultures of rVV-infected T2/L
 
d
 
 cells and tested
for CTL recognition. As shown in the third bar, T2/L
 
d
 
cells incubated with culture medium from rVV–sC-A9A–
infected cells were not lysed, and neither were T2/L
 
d
 
 cells
infected with rVV expressing the native secretory HBe
protein or the cytosolic cC-A9A chimera (
 
fourth bar
 
, and
data not shown). It could be argued that extracellular free
peptide has a short life without being bound to L
 
d
 
, but that
accumulation of complexes during the time of infection
with a continuous supply of free peptide would yield a suf-
ficient number of L
 
d
 
–9pp89 complexes for CTL recogni-
tion. To rule out these possibilities, 
 
51
 
Cr-labeled target cells
infected with native HBe-expressing rVV were coincu-
bated with cold rVV–sC-A9A–infected cells for 2 h before
the CTL assay. If there were extracellular antigenic pep-
tides, cold rVV–sC-A9A–infected bystander cells should
sensitize target cells. However, lysis was not observed (
 
sev-
enth bar
 
). The relevant control showing no interference of
cold cells with the CTL assay was provided by the recogni-
tion of labeled rVV–sC-A9A–infected targets at similar lev-
els in the presence or absence of cold rVV-HBe–treated
cells (
 
fifth 
 
and
 
 sixth bars
 
). To further prove that the epitope
recognized in rVV-sC-A9A–infected cells derives from en-
dogenously processed proteins, we used BFA, a drug that
blocks class I export beyond the 
 
cis
 
-Golgi compartment
(38) and prevents surface expression of class I–peptide com-
plexes of endogenous origin. The addition of BFA during
infection completely blocked presentation in sC-A9A–
infected T2/L
 
d
 
 cells, whereas it did not affect sensitization
by exogenous peptide (Fig. 2 
 
B
 
). These experiments show
compelling evidence that the pp89 peptide presented by
T2/L
 
d
 
 infected with rVV-sC-A9A is derived from endoge-
nous processing of the ER-targeted chimeric protein.
Figure 1. TAP-independent presentation to CTLs of secreted chimeric
HBe proteins. P13 TAP1 or T2/Ld TAP2 cells infected with rVV encod-
ing sC-A9A (filled triangles), cC-A9A (filled circles), sN-9 (filled diamonds),
eN-A9A (filled squares), or HBe (open circles) were confronted in a 51Cr-
release assay with 9pp89-specific CTLs restricted by H2-Ld. See Materials
and Methods for rVV nomenclature.
Figure 2. TAP-independent recognition
of 9pp89 by CTLs requires endogenous pro-
cessing of sC-A9A chimeric protein. (A)
51Cr-labeled T2/Ld target cells infected with
either rVV–sC-A9A or rVV-HBe or mock-
infected were incubated with 40 nM 9pp89
peptide, supernatant from rVV–sC-A9A–
infected T2/Ld cells, or cocultured with
rVV-infected cold cells as indicated, and
tested in a CTL assay. Recognition of rVV-
HBe– and rVV–sC-A9A–infected controls
without further treatment and of rVV–sC-
A9A–infected targets immediately after infec-
tion (0 h) are shown. Specific lysis at an E/T
ratio of 5:1 is shown. (B) Effect of BFA (filled
symbols) on recognition of 9pp89 peptide–
loaded (open triangles) and rVV–sC-A9A–
infected (open circles) T2/Ld cells by specific
CTLs. The negative control (solid line) was
provided by rVV-HBe–infected T2/Ld cells.1109 Gil-Torregrosa et al.
HBe and Derived Chimeric Proteins Mature in the Secretory
Pathway. Processing of HBe protein in the secretory
pathway generates four major molecular species that are
readily detected by Western blot with anti-HBe–specific
antiserum. Although not fully characterized, the heaviest
p25 form represents the full-length protein with the leader
peptide, intermediate p23 and p22 correspond to two
forms of the full-length protein lacking the signal sequence,
and the lightest p17e represents the final secretory form
(Fig. 3 A; reference 34). Some partially processed interme-
diates can also be detected, with different uncharacterized
cleavage points in the COOH-terminal region depending
on the cell type and the amount of protein being synthe-
sized. Exchange of the natural for the hemagglutinin-
derived signal sequence introduces a glycosylation signal at
Asn-3 that allowed monitoring transport of the different
forms through the secretory pathway at steady state. To
check processing of the chimeric proteins, cell lysates of
rVV-infected P13.1 cells were subjected to SDS-PAGE,
transferred to a membrane, and probed with an anti-HBe
antiserum (Fig. 3 B). Some differences can be observed in
the relative amounts of maturation intermediates of HBe
upon introduction of the A9A oligopeptide at the COOH-
terminal region, such as an increase in the molecular
weight of some of the forms and in the number of species
due to partial glycosylation of the signal sequence. How-
ever, the complex electrophoretic pattern of the different
intracellular molecular species detected with anti-HBe anti-
serum was unchanged overall. Similarly, introduction of
the pp89 epitope at the NH2-terminal region did not sig-
nificantly change the electrophoretic pattern of molecular
species at steady state, taking into consideration differences
in the expected molecular weights of the final and interme-
diate maturation forms (see sN-9 chimera). Tunicamycin
treatment of sC-A9A and sN-9 during rVV infection con-
firms that glycosylation at residue 23 is only partial, affect-
ing a minority of the ER-translocated protein, probably
due to its location at the very NH2 terminus. It also de-
creases the level of proteolytic maturation, both in nongly-
cosylable native HBe and in glycosylable chimeras, perhaps
by affecting proteases involved in their processing. Intro-
duction of a second glycosylation site in the 9pp89 epitope
of a chimeric secretory molecule by including an Ser resi-
due as a linker with the carrier protein (sN-9S) increased
the molecular weight of all sHBe forms, indicating that gly-
cosylation at this second site was complete and that all
forms detected had passed through the secretory pathway.
Treatment with tunicamycin confirms that essentially all of
the sN-9S detected forms had been glycosylated. As a con-
trol, equivalent cytosolic HBc NH2-terminal chimeras (not
shown) and cC-A9A were found to be single molecular
species, without evidence of further processing.
T2 cells infected with the different rVV were also ana-
lyzed to check the maturation pathway of the different chi-
meras. As in P13.1 cells, multiple forms of the protein were
found in the steady state by Western blot, differing only in
relative amounts between different chimeras. The signal
level of processed bands detected by Western blot of sC-
A9A protein in T2 cells was consistently lower than in
P13.1 (z10 versus 50%). This cannot be attributed to in-
creased transport through the secretory pathway, as se-
creted processed forms’ signals were also decreased in T2
cell extracellular media (data not shown). It is more proba-
bly due to a decreased level of proteolytic maturation. Gly-
cosylation of sC-A9A and sN-9 chimeras was also partial,
although more effective than in P13.1, and inhibitable by
tunicamycin, which also inhibited the maturation process,
reducing most of the total protein to a single nonglyco-
sylated form. sN-9S chimera was completely glycosylated
at the second site, demonstrating that all secretory chimeric
proteins were translocated into the ER, where they pro-
teolytically mature. Thus, all detectable species in sHBe-
derived proteins had been subjected to the glycosylation
machinery of the secretory pathway in both P13.1 and T2
cell lines, without any evidence of cytosolic resident forms,
which are otherwise stable, as can be detected in rVV-
HBc–infected cells.
Alteration of Maturation and Transport of HBe Through the
Secretory Pathway Affects Class I Presentation. We have shown
that the ER-targeted sHBe chimeric protein is processed in
the secretory pathway and that it is able to generate the
9pp89 epitope for class I–restricted antigen recognition.
We reasoned that altering maturation and transport of the
sHBe protein through the secretory pathway would affect
the outcome of 9pp89 presentation.
First, we checked the influence of BFA in maturation of
HBe-derived proteins to delimit the compartment in
which proteolysis of the COOH-terminal region may oc-
Figure 3. Maturation of HBe
and derived chimeric proteins.
(A) Schematic representation of
main HBe and HBc forms dur-
ing the maturation process.
Localization of 9pp89 epitope
(YPHFMPTNL) with flanking
residues in sC-A9A construct is
shown. aa, Amino acids. ss, Sig-
nal sequence. (B) Western blot
analysis of HBe-derived chimeras
in rVV-infected cells. Complete
cellular extracts of rVV-infected
P13 cells and rVV-infected T2/Ld cells in the presence or absence of tunicamycin (TM) or BFA (C) were separated by SDS-PAGE, transferred to a
membrane, and detected with an anti-HBe antiserum. Arrows, Positions of p22 and p17 HBe forms.1110 Exocytic Pathway Protease Furin Defines New MHC Class I Processing Route
cur. BFA destroys cis-Golgi compartmentalization by fusing
it with the ER, thus avoiding transport through the exo-
cytic pathway (38) and preventing antigen presentation
(Fig. 2 B). As seen in Fig. 3 C, BFA treatment blocks mat-
uration of HBe-derived proteins, reducing by .90% the
amount of processed protein detected at the steady state,
both in P13.1 and T2 cells, without affecting the cytosolic
cC-A9A chimera. Thus, we conclude that proteolytic mat-
uration of HBe proteins requires transport of the immature
protein to the Golgi compartment and that it must occur in
the Golgi or a post-Golgi compartment.
Second, we checked the influence of pepstatin in the
recognition by specific CTLs of T2/Ld cells infected with
sC-A9A. It has been previously shown that pepstatin, an
inhibitor of aspartyl proteases which participate in either
processing of inactive proproteins to mature polypeptides
in the secretory pathway or which are active in lysosomal
compartments (39), is able to inhibit secretion of processed
HBe (36) with accumulation of intermediate processing
forms. As seen in Fig. 4 A, 100 mM pepstatin completely
abrogates secretion of processed forms of sC-A9A in T2/Ld
cells while only partially inhibiting secretion of complete
forms (z40%, as revealed by densitometric analysis of elec-
trophoretic bands). Analysis of the intracellular protein
pool shows a concomitant dose-dependent increase of par-
tially and fully processed species relative to the nonpro-
cessed forms. The former reach 30% of the amount of full-
length forms’ signal detected instead of the usual 10% in the
steady state of nontreated cells. In addition, treatment with
pepstatin produced a general decrease in the total amount
of intracellular sC-A9A proteins detected, reaching a 50%
decrease at 100 mM, which parallels the diminished levels
of extracellular full-length proteins.
This alteration of the biochemical pathway of HBe mat-
uration had direct consequences for the generation of
9pp89 epitope. T2/Ld target cells treated with pepstatin
presented more Ld–9pp89 complexes at the cellular surface,
as indicated by increasing dose-dependent levels of CTL
recognition (Fig. 4 B). This effect was specific for the gen-
eration of the antigenic epitope, as recognition of peptide-
loaded target cells was not affected. Therefore, intracellular
accumulation of intermediates of processing of the COOH-
terminal region of the chimeric protein in the secretory
pathway increased class I presentation by providing more
antigenic peptide for class I loading, strongly suggesting
that the peptide epitope is being generated in the secretory
pathway. On the other hand, no connection was found be-
tween the full-length proteins detected in the extracellular
medium and recognition by CTLs.
Proteasomes Are Not Involved in 9pp89 Processing in the
Secretory Route. It has recently been shown that many
proteins that were supposed to be degraded in the ER are
in fact digested in the cytosol by the general cytosolic ubi-
quitin-dependent degradative machinery of proteasomes,
probably after retrograde transport of the polypeptide
through the protein-conducting translocon channel (40,
41). In our case, it would be difficult to explain why such
cytosolic processing of sC-A9A would yield a product able
to be translocated back into the ER by a TAP-independent
mechanism, when such a product is not produced from the
otherwise identical, except for the lack of the 10 NH2-ter-
minal amino acids, cytosolic cC-A9A protein. Despite this,
we decided to test if proteasomes could be involved in gen-
erating the 9pp89 epitope from the secretory protein sC-
A9A. Lactacystin is perhaps the most specific and efficient
inhibitor of proteasomes, as it covalently binds the b cata-
lytic subunits (12). T2/Ld cells were extremely sensitive to
lactacystin, and toxic effects occurred upon long exposure
or at high concentrations. For this reason, to test the possi-
ble involvement of proteasomes in 9pp89 processing, T2/
Ld cells were preincubated with lactacystin and then infected
for a shorter time period in the presence of 10 mM lactacys-
tin. As shown in Fig. 5 A, lactacystin treatment did not affect
T cell recognition of sC-A9A–infected T2/Ld cells. Addition
of BFA at the time of CTL assay to prevent additional anti-
gen presentation did not alter the result (data not shown).
The effect of proteasome inhibition was additionally tested
in P13.1 cells infected with rVV encoding the secretory or
cytosolic chimeras. These cells were also slightly sensitive to
lactacystin treatment, as recognition of 9pp89 peptide–
loaded uninfected cells was subtly inhibited, to the same
extent as sC-A9A infected cells (not shown). Nevertheless,
recognition of cC-A9A–infected cells was completely abro-
gated even at concentrations 1/3 lower than for sC-A9A
(Fig. 5 B), indicating specific involvement of proteasomes in
antigenic processing of the cytosolic chimera. Similarly, pre-
sentation of cytosolic versus secretory chimeras was also
selectively sensitive to lactacystin treatment in L/Ld transfec-
tants (data not shown). Therefore, we concluded that most
of the 9pp89 peptide presented by Ld in sC-A9A–infected
TAP1 and TAP2 cells is generated independently of the
general cytosolic processing pathway of proteasomes.
Proteases of the Secretory Pathway Are Involved in Antigen
Presentation. We have shown conclusive evidence that
Figure 4. Effect on maturation and antigen presentation of alteration of
the secretory pathway by pepstatin. (A) Cell extracts and supernatant cul-
ture medium of T2/Ld cells infected with rVV–sC-A9A and treated with
the indicated amounts of the aspartic protease inhibitor pepstatin were an-
alyzed by Western blot with HBe-specific antiserum. (B) CTL recogni-
tion of T2/Ld cells infected with rVV–sC-A9A (open circles) and treated
with 100 mM (filled circles), 25 mM (filled diamonds), and 6.25 mM (filled
squares) pepstatin. A control of 9pp89 peptide–loaded target cells (filled trian-
gles) treated or untreated (open triangles) with pepstatin is included. The neg-
ative control (solid line) was provided by rVV-HBe–infected T2/Ld cells.1111 Gil-Torregrosa et al.
processing for class I loading of the secretory sHBe core
protein takes place in the secretory pathway. Which pro-
teases could be involved in this new pathway? The 193
amino acid–long HBe core protein has a peculiar COOH-
terminal region characterized by an accumulation of 16 ba-
sic Arg residues in the 150–179 segment (Fig. 3 A). This
region is clipped off during maturation in the secretory
pathway, generating the final secretory p17 form that en-
compasses amino acids 210 to 147/9. Several proteases
specific for dibasic residues are known to participate in pro-
teolysis of protein precursors to generate their mature
forms (26). Furin, a trans-Golgi network (TGN) resident
protein known to participate in processing of several pro-
proteins, such as peptide hormones and viral glycoproteins,
has a specificity for an RXR/KR motif (42), which occurs
three times at the COOH-terminal region of the HBV
core protein. We speculated that furin could be involved in
the processing of HBe for generation of both the secreted
forms and the 9pp89 epitope located after this region in the
chimeric sC-A9A protein. The peptidyl chloromethylke-
tone decRVKR-CMK, a furin-specific inhibitor due to its
mimicry of the four amino acid binding motif (29), was
used to assess the involvement of this protease in sC-A9A
processing. Incubation of rVV–sC-A9A–infected T2/Ld
targets with the furin inhibitor produced a specific dose-
dependent inhibition of CTL recognition (Fig. 6 A), with-
out toxic effects to the peptide-loaded control targets (data
not shown). Further, if we also added the inhibitor during
the CTL assay, complete abrogation of CTL recognition
could be observed at a 10-fold lower dose than when only
added during the infection phase (compare 8 mM* with 75
mM). This is consistent with the reversible and unstable na-
ture of the inhibitor, and did not unspecifically inhibit CTL
recognition of peptide-loaded targets (data not shown).
Abrogation of antigen presentation correlated with inhibi-
tion of proteolytic maturation of the HBe protein in the
secretory pathway. Fig. 6 B shows that decRVKR-CMK
inhibited maturation of sC-A9A both in T2 and P13.1 cells
in a dose-dependent manner. In T2/Ld, decRVKR-CMK
is more effective, inhibiting appearance of final processing
products even at low doses. As a consequence, secretion of
the processed forms to the external medium was also abro-
gated by inhibitor activity, as was proteolytic maturation of
native HBe and NH2-terminal secretory chimeras (data not
shown). In P13.1 cells, generation of all processed products
was partially inhibited at low doses (8 mM concentration),
but high doses (75 mM) were necessary to prevent detec-
tion of all processed forms (at 25 mM, processed lower
bands’ signal still constitutes z4% of the total intracellular
detected protein). Therefore, higher doses of inhibitor
would be needed to prevent generation of the 9pp89
epitope in P13.1 cells. This would explain why treatment
of P13.1 targets did not essentially affect the level of CTL
recognition (data not shown). Alternatively, sC-A9A might
be processed by either pathway in P13.1 cells, and the pres-
ence of one of them alone might suffice for antigen presen-
tation. Thus, proteolytic cleavage of the COOH-terminal
region of HBe protein by furin or other proteases of similar
specificity is absolutely necessary for processing the 9pp89
epitope from the chimeric protein in the secretory pathway
for class I presentation. We do not know which cleavage
points are involved, if furin action involves a progressive
proteolysis at the different potential sites, or if all or some
sites are affected independently during HBe processing.
Whichever COOH-terminal peptides are clipped off, the
action of additional proteases on both sides of the 9pp89
epitope might be required to produce an antigenic peptide
suitable for Ld binding and CTL recognition.
Nature and Quantity of 9pp89 Processed Peptides Generated
by TAP-dependent and -independent Routes. We have seen
Figure 5. Effect of the proteasome inhibitor lactacystin (LC) on anti-
gen presentation of HBe-derived chimeric proteins. Recognition by
9pp89-specific CTLs of cell lines T2/Ld and P13.1 infected with rVV–
sC-A9A (open circles) or rVV–cC-A9A (open triangles) treated with lactacys-
tin (filled symbols) 10 mM in the case of T2/Ld cells, 30 mM for rVV–cC-
A9A–infected P13.1, and 100 mM for rVV–sC-A9A–infected P13.1 cells
is shown. The negative control (solid line) was provided by rVV-HBe–
infected cells.
Figure 6. Furin inhibitor decRVKR-CMK inhibits maturation and
antigen presentation of sC-A9A protein. (A) CTL recognition of rVV–
sC-A9A–infected T2/Ld cells untreated (open circles) or treated with furin
inhibitor (filled symbols) at the indicated concentrations. 8 mM* (filled cir-
cles) signifies that a second addition of 8 mM decRVKR-CMK was per-
formed before CTL assay. The negative control (solid line) was provided
by rVV-HBe–infected T2/Ld cells. (B) Cell extracts from rVV–sC-A9A–
infected T2/Ld and P13.1 cells treated with the indicated amounts of dec-
RVKR-CMK during infection were analyzed by Western blot with an
anti-HBe antiserum. In the 8* lane, a second addition of 8 mM dec-
RVKR-CMK was performed 3 h before cell harvesting.1112 Exocytic Pathway Protease Furin Defines New MHC Class I Processing Route
how 9pp89 in HBe-derived chimeric proteins can be pro-
cessed and presented by Ld by the normal TAP-dependent
pathway or by a new, TAP-independent route, depending
on its intramolecular location and the compartment target-
ing of the carrier protein. It is possible that different anti-
genic epitopes with the 9pp89 core sequence would be
generated by the two routes. To test this possibility, we
prepared acid extracts of rVV-infected cells and fraction-
ated them by reversed-phase HPLC. Individual fractions
were then used to sensitize P13.1 cells and were confronted
with 9pp89-specific CTLs. Fig. 7 A, left, compares the
chromatographic profile of peptide cell extracts from T2/
Ld and L/Ld cells infected with either rVV–sC-A9A or
rVV–cC-A9A. As expected, in T2/Ld cells expressing the
cytosolic cC-A9A chimera, antigenic peptide could not be
detected. In contrast, when expressing the secretory sC-
A9A protein, two peaks of CTL activity were found, the
same peaks as in TAP1 L/Ld cells expressing either chi-
mera. Previous work in our laboratory has demonstrated
that the peak at fraction 69 coelutes with the pp89 optimal
9-mer YPHFMPTNL epitope, whereas the first peak cor-
responds to the oxidized form of the peptide at the me-
thionine residue (3). This oxidation does not result in any
decrease in antigenicity, as assessed with oxidized synthetic
peptide (data not shown). In summary, the two processing
pathways generated peptides of the same chromatographic
mobility recognized by CTLs, strongly suggesting that both
routes generate the same final optimal epitope.
But although the same final products were generated by
both pathways, they differed in their need for Ld for stabili-
zation, supporting our claim that they are produced in dif-
ferent environments. This was revealed when an equivalent
peptide extraction experiment was performed in cells that
do not express Ld (Fig. 7 A, right). In T2 and Ltk2 cells, al-
though no antigenic material was present in the cytosolic
cC-A9A, both antigenic peaks were unexpectedly detected
for the ER-targeted chimera. Quantitative analysis testing
dilutions of the active fractions in the CTL assay shows that
peptide yield was some 25-fold higher in L/Ld than in T2/
Ld cells for the secretory chimera, probably due to the dif-
ference in cell types, whereas the reverse ratio was found
for the Ld2 cells (Fig. 7 B). The antigenic peptide derived
from cC-A9A in L cells was rescued from cytosolic degra-
dation and stabilized by Ld by more than 2,000-fold (Fig.
7 B). In contrast, the peptide generated by the secretory
route from sC-A9A was only slightly more abundant in
T2/Ld than in T2 cells, indicating that binding to Ld was
not significantly required to stabilize this free peptide. This
is consistent with our previous experiments suggesting that
sC-A9A is processed in the exocytic pathway, a less degra-
dative environment than the cytosol (43), and thus could
be partially stable in the absence of Ld. Since in TAP2 cells
Ld molecules would be avidly awaiting the appropriate
peptides for binding, it is reasonable to assume that most of
the 9pp89 peptide generated in the secretory pathway was
bound to Ld. Analogously, 9pp89 is also found in Ltk2 cells
expressing the secretory sC-A9A but not the cytosolic cC-
A9A chimera, further confirming the compartmental origin
of the epitope even in TAP1 cells. In contrast to T2 cells,
in TAP1 L cells, z700-fold more sC-A9A–derived peptide
was detected in the Ld transfectant (Fig. 7 B), indicating
that it was stabilized by Ld more than in T2 cells but cer-
tainly less than the cytosolic peptide in these same L cells
(see above). This suggests that the degradative environment
for the secretory 9pp89 peptide might be much stronger in
TAP1 Ltk2 than in TAP2 T2 cells. Alternatively, both the
secretory and the cytosolic pathways might be operating in
processing sC-A9A in the TAP1 cells, so that what we see
is a combination of both. In summary, based on these find-
ings, we conclude first that the final product of processing
in the secretory pathway is the same as in the cytosolic
route, and second that 9pp89 produced in the secretory
pathway as a result of COOH-terminal processing of the
full-length HBe protein is relatively protected from degra-
dation in a class I–independent manner, as it does not have
direct access to the cytosolic degradation machinery.
Figure 7. Characterization and quantita-
tion of naturally processed antigenic pep-
tides in cell extracts. Acid-soluble extracts
prepared from T2/Ld (filled circles), T2 (filled
diamonds), L/Ld (filled squares), or Ltk2 (filled
triangles) cells infected with rVV–sC-A9A
(filled symbols) or rVV–cC-A9A (open sym-
bols) and fractionated by reverse-phase
HPLC were tested for their ability to sensi-
tize P13 cells for lysis by 9pp89-specific
CTLs. (A) Detection of peptides by 9pp89-
specific CTLs after HPLC fractionation of
whole cell extracts. Each test well contained
9 3 106 cell equivalents. (B) Peptide quanti-
tation by CTL recognition of serial dilutions
of antigenic fractions. The average of spe-
cific lysis of fractions 62 and 69, the peaks of
the two CTL-reactive peptide forms, is
shown. 10% average specific lysis was cho-
sen as the minimum level for considering
positive T cell recognition and comparison
among different rVV and lines.1113 Gil-Torregrosa et al.
Discussion
It is generally agreed that the vast majority of endoge-
nous peptides presented by MHC class I molecules derive
from proteins degraded in the cytosol by proteasomes and
transported into the ER by the TAP heterodimer. In addi-
tion, some studies have shown the potential existence of al-
ternative, proteasome/TAP-independent pathways for an-
tigen presentation of full-length proteins (24, 25). Because
the mechanisms involved remain uncharacterized to date,
the question is open on the possibility of antigen processing
in the ER and secretory route.
In this report, we address that question. We describe a
mechanism that allows antigen processing and presentation
in the secretory pathway of a proprotein that is naturally
processed to a secreted form. Maturation in the exocytic
route of the HBV HBe core protein results in a form that is
specifically secreted to the medium, and involves pro-
teolytic cleavage of its 24 COOH-terminal amino acids
(35). We have examined antigen presentation by class I Ld
molecules of the reporter epitope 9pp89 engineered in the
COOH terminus of an HBe-derived chimeric protein.
The epitope in an endogenously synthesized ER-targeted
chimera is presented by TAP2 cells, whereas chimeras with
the epitope located at the NH2 terminus or cytosol-tar-
geted chimeras are not presented. TAP-independent anti-
gen presentation to CTLs occurs via an endogenous path-
way that is independent of lactacystin-sensitive proteasomes,
and the ER-targeted chimeras effectively enter the ER as
they are fully glycosylated. Inhibition by BFA and correla-
tion of correct protein maturation with effective antigen
presentation locate the point of antigen processing at the
Golgi or a post-Golgi compartment. The use of a furin-
specific inhibitor identifies the TGN-resident protease furin,
or proteases with similar specificity for polybasic residues,
as critical for liberating intermediate COOH-terminal pep-
tides that are eventually further processed to the final anti-
genic optimal 9pp89 peptide, probably by exopeptidase trim-
ming, thus characterizing this novel mechanism of antigen
processing in the exocytic pathway.
This route is not an exception to common rules of pro-
protein and antigenic processing. In fact, many proteins are
cleaved during their maturation process in the exocytic
pathway, generally at two or more contiguous dibasic resi-
dues by proteases of the subtilisin family (26). Among
them, seven viral glycoproteins have been described to ma-
ture by this mechanism (42), which would make them
available for antigen processing by this route. The advan-
tage of HBe for antigen presentation is that cleavage occurs
at a point close to the COOH-terminal end of the protein,
generating relatively small peptides that could be processed
to antigenic forms by mere trimming by exopeptidases.
Trimming capacity in the ER or the secretory route has
been suggested by a number of experiments, generally in-
volving signal sequence–mediated targeting of minigenes
or truncated proteins with an antigenic epitope to the ER
(21, 22, 44). The signal peptidase liberates the epitope from
minigene products in the compartment where peptide
loading normally occurs, leading to very effective antigen
presentation. If that epitope is accompanied by flanking re-
gions besides the signal sequence, antigen presentation will
occur with different efficiency, following the COOH-end
rule, which suggests that trimming to the optimal antigenic
size is more effective if the epitope is located at the COOH
end of the oligopeptide rather than at the NH2 terminus
(17, 21). In our case, the antigenic epitope is located at po-
sition 179 of the sHBe chimera, flanked by five alanine res-
idues on both sides and six extra residues at the COOH
end. Peptides generated by the proteolytic action of furin
in the secretory pathway would have a maximum of 50 and
a minimum of 29 amino acids, with 9pp89 located at 11
residues from the COOH end in all cases. Therefore, a
minimum of 9 NH2-terminal residues and 11 COOH-ter-
minal residues must be trimmed from the precursor peptide
to generate the optimal 9pp89 epitope, which is generated
by this alternative as well as by the classic proteasome/
TAP-dependent route, and thus both amino- and carboxy-
peptidases may be involved.
It is somewhat surprising that the same final antigenic
peptide is produced by the cytosolic proteasome-depen-
dent pathway and by this new secretory route. Although
data (not shown) with other related constructs from our
laboratory reveal that these polyclonal 9pp89-specific CTLs
are able to detect other endogenous uncharacterized 9pp89-
related peaks in HPLC fractions, they are probably biased
to better detect the optimal 9pp89 peptide and thus might
miss precursor intermediates generated with different effi-
ciency by each pathway. Alternatively, the same final pep-
tide would be generated by both routes if similar enzymes
were involved in the final trimming of potential precursor
peptides in the exocytic route.
Degradation of ER-resident or targeted proteins has
been proven to occur not in the ER but in the cytosol, un-
der the control of the ubiquitin-proteasome pathway (41).
Recruitment of cytosolic ubiquitinating enzymes to the
ER membrane is necessary not only for proteasome degra-
dation of ER proteins, but also for retrograde transport out
of the ER of the lumenal substrate to be degraded (45).
This pathway is most probably not involved in processing
of 9pp89 in the ER-targeted sC-A9A chimera. First, in our
case, antigen presentation is not related to degradation of
the protein, but rather to maturation to shorter secretable
forms, liberating a short peptide suitable for further trim-
ming, as deduced from the pepstatin and furin inhibitor
experiments. Second, degradation of ER proteins is com-
pletely inhibited by the proteasome-specific inhibitor lacta-
cystin, whereas no influence has been detected in CTL rec-
ognition of rVV–sC-A9A–infected TAP1 or TAP2 cells.
Third, there is no obvious explanation for why processing
of retrograde translocated ER-targeted chimeras would
generate a peptide able to trespass the ER membrane in a
TAP-independent fashion, while the same does not apply
to the equivalent cytosolic cC-A9A chimera, which differs
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In addition, ER-targeted chimeras with A9A located at the
NH2-terminal region cannot be recognized in T2/Ld cells,
implying that this putative TAP-independent peptide can-
not be generated in the cytosol in other types of constructs.
Most probably, the fact that the NH2 terminus of the pro-
tein is not affected by proteolytic maturation explains the
absence of CTL recognition, as indicated by the inhibition
of presentation of the COOH-terminal chimera by the fu-
rin inhibitor. Thus, processing of 9pp89 in this new path-
way conforms to all expectations for class I presentation,
and is fully explainable by proteolytic mechanisms previ-
ously described for the exocytic route.
Could other compartments be involved in further pro-
cessing the precursor peptides liberated by the proteolytic
activity of furin? It is possible that precursor peptides can be
transferred to endocytic or lysosomal vesicles where further
processing could occur. Agents that inhibit lysosomal deg-
radation by increasing pH, such as chloroquine, also affect
furin activity (29), which is active at neutral and mildly
acidic pH, and therefore inhibit 9pp89 presentation in T2/
Ld cells (data not shown). Leupeptin, an inhibitor of many
lysosomal proteases, did not influence CTL recognition
(data not shown), although this result does not discard in-
volvement of minor lysosomal proteases. Again, liberation
to the cytosol of a peptide with the capacity to be translo-
cated into the ER in a TAP-independent fashion should be
postulated. Alternatively, the final antigenic peptide gener-
ated in the lysosomal pathway would reach recycling Ld
molecules in endocytic vesicles and be bound and reex-
ported to the cell membrane (46).
The question arises as to where in the secretory route
loading of 9pp89 to Ld occurs. Two possibilities are sug-
gested. The first is that a retrograde gradient of 9pp89 pep-
tide or precursor peptide is generated in the secretory path-
way from its generation point at the TGN. Retrograde
transport of peptides from the TGN to the ER has been
demonstrated to be specific and dependent on retrieval sig-
nal KDEL (47). Recently, constitutive retrograde transport
to the ER of Golgi-localized or even TGN-resident pro-
teins lacking retrieval signals has been demonstrated (48).
Thus, specific or constitutive retrograde transport may oc-
cur, and sufficient amounts of 9pp89 could travel to the
traditional loading compartment for class I molecules in the
ER, where binding to nascent Ld molecules could occur.
Alternatively, the small proportion of functionally empty
class I molecules that travel through the exocytic pathway
to the cell membrane bind peptides generated in the TGN.
In our case, these peptide-empty molecules, named Ldalt
for their different conformation (49), would bind either
fully processed optimal 9pp89 epitope or the 9pp89 precur-
sor liberated by furin that would be trimmed in its bound
conformation.
Surprisingly, quantitative analysis of the peptide content
of cell extracts shows that 9pp89 peptide from the secretory
sC-A9A chimera is stable in the absence of Ld in both T2
and Ltk2 cells, whereas it cannot be detected in cells ex-
pressing the cytosolic cC-A9A protein. This evidence strongly
suggests that 9pp89 from sC-A9A is produced in a com-
partment where it is at least partially protected from the
degradative machinery of the cytosol, such as the secretory
pathway (43). This is supported by the fact that T2 cells ex-
pressing  Ld have analogous amounts of 9pp89 peptide as
Ld2 cells. 9pp89 is significantly more abundant in T2 than
in L cell lines in the absence of Ld, despite the fact that L
cells produce more peptide as deduced from comparison of
Ld-expressing L and T2 cells. This can be accounted for by
the fact that lack of TAP transporters in T2 may also affect
chaperones of the secretory pathway specialized in peptide
binding, such as gp96, protein disulfide isomerase, or BiP,
which would also be deprived of their normal peptide supply
(50–53). Thus, even in the absence of stabilizing class I mole-
cules, most of the 9pp89 peptide generated in the secretory
pathway in T2 cells could be stabilized by resident chaperones
which otherwise would be occupied by TAP-dependent
peptides, as occurs in L cells. Another explanation might be
that TAP not only participates in importing peptides from the
cytosol, but also exports peptides in a less specific and effec-
tive way, as demonstrated recently for Sec61 translocon (40).
This would effectively diminish the amount of free 9pp89
peptide in the ER of L cells without applying to T2 cells. In
any case, the different behavior of cytosolic and secretory
chimeras strongly supports our conclusion that 9pp89 is
generated by processing in the secretory pathway without in-
tervention of more degradative compartments (43).
We do not know the significance of this alternative pro-
cessing route in TAP1 cells. The fact that T2 and T2/Ld
cells have analogous amounts of 9pp89 peptide strongly
suggests that all peptide presented by T2/Ld is produced in
the secretory route. Unfortunately, furin inhibitor com-
pletely blocks neither protein maturation nor antigen pre-
sentation in P13.1 cells, probably due to the high level of
sC-A9A maturation, precluding us from testing the contri-
bution of this route to antigen presentation in TAP1 cells.
It is possible that conventional processing by the protea-
some machinery of aberrant or mistargeted sC-A9A pro-
tein would provide enough antigenic 9pp89 peptide for
CTL recognition, but this is clearly a minor contribution,
as lactacystin treatment does not influence antigen presen-
tation from sC-A9A while it prevents recognition of cyto-
solic chimeras, despite both producing similar amounts of
9pp89 peptide. Therefore, although both routes probably
coexist, we feel that the contribution of processing in the
secretory pathway is more relevant to presentation of
9pp89 epitope from the secretory protein.
We have shown that an antigenic epitope localized at a
region of an ER-targeted protein cleaved off during matu-
ration can be efficiently presented in the absence of TAP
peptide transporters. This new route, which we describe
for the first time, might not be exclusive of HBe protein,
but probably applies to other secretory molecules known to
mature in the secretory pathway and may be responsible for
presentation of some natural viral antigens, as a number of
viral glycoproteins do proteolytically mature in the exo-
cytic route (29, 42). The strategy described in this report
may constitute a novel and efficient means of vaccinating
for subdominant epitopes, as it would bypass the processing1115 Gil-Torregrosa et al.
hierarchy of the proteasome–TAP system that is often unable
to generate sufficient amounts of a class I–specific peptide to
mount a primary response, although it may provide enough
peptide for T cell recognition and secondary responses.
Thus, it would be possible to induce a more diverse response
against a given antigen using several epitopes, increasing the
chances of a more effective effector phase, which would lead
to a more efficient immune response.
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